Quotient Sciences - Philadelphia
United States
Program data pending ClinicalTrials.gov matching
Profiled
Not yet scored
✓ FDA Inspections (2)
○ Clinical Trials
○ SEC Filings
✓ Press (10)
○ EMA GMP
○ MHRA GMP
✓ HC GMP (4)
Quick Facts: Quotient Sciences - Philadelphia
- Signal Score
- Profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed. How scoring works
- Headquarters
- United States
- Website
- https://www.quotientsciences.com/
- Modalities
- Small Molecule API, Oral Solid Dose
- Active Programs
- No ClinicalTrials.gov matches confirmed
- Data Sources
- FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
About Quotient Sciences - Philadelphia
Quotient Sciences - Philadelphia is a contract development and manufacturing organization (CDMO). Capabilities: Small Molecule API, Oral Solid Dose. 2 manufacturing sites registered with the U.S. FDA and Health Canada. Website: https://www.quotientsciences.com/
Signal Score
Profiled, not yet scored.
Scores are published after regulatory evidence is attached and reviewed.
How scoring works
Quotient Sciences - Philadelphia FDA Inspection History
2025-09
2022-12
NAI
VAI
OAI
| Date | Site | Type | Observations | Classification |
|---|---|---|---|---|
| 2025-09-17 |
Quotient Sciences - Philadelphia, LLC
Boothwyn, Pennsylvania
Company-level
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
| 2022-12-22 |
Quotient Sciences - Philadelphia, LLC
Boothwyn, Pennsylvania
Company-level
|
Drug Quality Assurance | Yes | Voluntary Action Indicated (VAI) |
Source: FDA Data Dashboard · Retrieved Oct 31, 2026
Quotient Sciences - Philadelphia FDA 483 Findings 4 observations · 2022-12-22 → 2025-09-17 ?
By subsystem
By severity
- 2 — Minor: 4
- Repeat observations: 1
Most severe findings
-
Cleaning / Sanitizing / Maintenance
"Equipment and utensils are not cleaned, maintained and sanitized at appropriate intervals to prevent contamination that would alter the safety, identity, strength, quality or purity of the drug product."
-
Written procedures not established/followed
"Written procedures are not followed for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product."
-
Protective Apparel Not Worn
"Protective apparel is not worn as necessary to protect drug products from contamination."
Hiring Activity Beta
Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source:
public careers pages
· Checked Oct 30, 2026
Company Signals 10 articles
Company announcements, not verified evidence. They do not change any score.
Acquisitive Quotient buys CDMO Pharmaterials, reveals new identity - Fierce Biotech
Pharma in 2025–2026: AI, China and the new era of drug development - Manufacturing Chemist
Thierry Van Nieuwenhove Appointed as CEO of Quotient Sciences - CHEManager
Quotient Sciences and Biorasi partner to accelerate early phase clinical trials to patient proof-of-concept - PR Newswire
Quotient Sciences Acquires Arcinova, the UK-Based Contract Development and Manufacturing Organization - Business Wire
CEO Spotlight: Thierry Van Nieuwenhove - Contract Pharma
CDMO Roundtable: Managing Orphan Drug Projects - DCAT Value Chain Insights
Quotient Sciences casts $8.7M spell over its new Alnwick facility, adding drug substance capacity and 80 jobs - Fierce Pharma
CDMO Quotient extends Ipsen supply pact for rare disease drug Sohonos - Fierce Pharma
Quotient's streamlined drug development process saves months - Pharmaceutical Technology
Frequently Asked Questions About Quotient Sciences - Philadelphia
How many FDA inspections does Quotient Sciences - Philadelphia have on record?
CDMO Signal tracks 2 FDA inspections for Quotient Sciences - Philadelphia, sourced from the FDA inspection database. See the full inspection history above.
Has Quotient Sciences - Philadelphia received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Quotient Sciences - Philadelphia.
Does Quotient Sciences - Philadelphia have a CDMO Signal Score?
Not yet. Quotient Sciences - Philadelphia is profiled, not yet scored. Scores are published after regulatory evidence is attached and reviewed.
Evaluating Quotient Sciences - Philadelphia for a manufacturing program?
Use the free AI matchmaker to compare Quotient Sciences - Philadelphia against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
Similar CDMOs
Alcami Carolinas
United States
Oral Solid Dose, Sterile Fill-Finish, Small Molecule API
Almac
United Kingdom
Small Molecule API, Oral Solid Dose, Packaging & Labeling
AbbVie Contract Manufacturing
North Chicago, Illinois, United States
Small Molecule API, High-Potency APIs, Biologics, ADC / Bioconjugation, Sterile Fill-Finish, Lyophilization, Prefilled Syringes, Oral Solid Dose, Hot-Melt Extrusion, Oral Liquids, Topicals
Esjay Pharma
East Windsor, New Jersey, United States
Oral Solid Dose, Softgels, Oral Liquids, Small Molecule API
Apertus Pharmaceuticals
St. Louis, Missouri, United States
Oral Solid Dose, Topicals, Finished Dosage Forms, Small Molecule API
Compare Quotient Sciences - Philadelphia with another CDMO
Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.